Texas Sen. John Cornyn sounded the alarm that a biotech startup firm that has raised some $30 million to study diseases in embryos is working on gene-editing techniques for humans at their earliest stages.
Want more insights? Join Working Title - our career elevating newsletter and get the future of work delivered weekly.
